Johnson & Johnson (JNJ) Free Cash Flow (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Free Cash Flow came in at $1.5 billion in Q1 2026, down 56.64% year-on-year from $3.4 billion in Q1 2025, and down 73.23% quarter-over-quarter from $5.5 billion in Q4 2025.
Johnson & Johnson (JNJ) Free Cash Flow (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Free Cash Flow across 18 years of filings, most recently posting $1.5 billion for Q1 2026.
- Free Cash Flow for Q1 2026 came in at $1.5 billion, down 56.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.8 billion (down 12.7% YoY), and the FY2025 annual result was $19.7 billion, down 0.73% from the prior year.
- Free Cash Flow came in at $1.5 billion for Q1 2026 at Johnson & Johnson, down from $5.5 billion in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $8.0 billion in Q3 2025 to a low of $1.5 billion in Q1 2026.
- The 5-year median for Free Cash Flow is $3.4 billion (2025), against an average of $4.3 billion.
- Across the five-year window, Free Cash Flow surged 259.75% in 2023 and sank 56.64% in 2026, its largest moves.
- Johnson & Johnson's Free Cash Flow stood at $3.4 billion in 2022, then jumped by 86.06% to $6.3 billion in 2023, then declined by 14.39% to $5.4 billion in 2024, then gained by 1.88% to $5.5 billion in 2025, then tumbled by 73.23% to $1.5 billion in 2026.
- The last three Free Cash Flow figures came in at $1.5 billion (Q1 2026), $5.5 billion (Q4 2025), and $8.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 2.12 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 1.47 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.56 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 757.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | 346.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 1.47 Bn |
| Mar 29, 2026 | 1.47 Bn |
| Dec 28, 2025 | 5.47 Bn |
| Dec 28, 2025 | 5.47 Bn |
| Sep 28, 2025 | 8.01 Bn |
| Sep 28, 2025 | 8.01 Bn |
| Jun 29, 2025 | 2.84 Bn |
| Jun 29, 2025 | 2.84 Bn |
| Mar 30, 2025 | 3.38 Bn |
| Mar 30, 2025 | 3.38 Bn |
| Dec 29, 2024 | 5.37 Bn |
| Dec 29, 2024 | 5.37 Bn |
| Sep 29, 2024 | 6.96 Bn |
| Sep 29, 2024 | 6.96 Bn |
| Jun 30, 2024 | 4.66 Bn |
| Jun 30, 2024 | 4.66 Bn |
| Mar 31, 2024 | 2.85 Bn |
| Mar 31, 2024 | 2.85 Bn |
| Dec 31, 2023 | 6.27 Bn |
| Dec 31, 2023 | 6.27 Bn |